セミプリマブで治療された固形がんの成人参加者における89Zr-DFO-REGN5054を使用したImmunoPetイメージングの研究
セミプリマブで治療された固形悪性腫瘍患者における 89Zr-DFO-REGN5054 (抗 CD8) 陽電子放出断層撮影法に関する初めての研究
This study is researching an experimental drug called 89Zr-DFO-REGN5054 and cemiplimab. The study is focused on patients with a type of cancer that can be potentially imaged using 89Zr-DFO-REGN5054 and show special tumor features that may be important to the way the immune system fights cancer.
The aim of the study is to study the safety and tolerability (how the body reacts to the drug) of the imaging agent 89Zr-DFO REGN5054.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drugs
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects)
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
-
Groningen、オランダ、9700 RB
- UMC Groningen
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Advanced or metastatic solid tumors that may respond to anti-programmed cell death 1 (PD-1) immunotherapy
- Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
- Adequate organ and bone marrow function as defined in the protocol
- Willing and able to comply with clinic visits and study-related procedures (including required tumor biopsy for Part B)
Key Exclusion Criteria:
- Currently receiving another cancer treatment or inadequate time since last therapy, as defined in the protocol
- Has not yet recovered from acute toxicities from prior therapy; exceptions defined in the protocol
- Prior treatment with a blocker of the PD-1/Programmed death ligand 1 (PD-L1) pathway
- Currently receiving or has received chimeric antigen receptor (CAR-T) cell therapy
- Symptomatic or untreated brain metastases, leptomeningeal disease, or spinal cord compression
- Known history of or any evidence of interstitial lung disease, active, noninfectious pneumonitis (past 5 years) or active tuberculosis
NOTE: Other protocol defined inclusion/exclusion criteria apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Single ascending dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab
Part A: Doses of 89Zr˗DFO˗REGN5054 may be reduced based upon assessment. |
Administered by intravenous (IV) infusion during Part A and B. Administered by IV infusion every 3 weeks (Q3W).
他の名前:
|
|
実験的:Defined dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab
Part B: Defined dose of 89Zr˗DFO˗REGN5054 determined in Part A. |
Administered by intravenous (IV) infusion during Part A and B. Administered by IV infusion every 3 weeks (Q3W).
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
時間枠:Up to day 8, after the infusion of 89Zr˗DFO˗REGN5054
|
Part A |
Up to day 8, after the infusion of 89Zr˗DFO˗REGN5054
|
|
Incidence and severity of TEAEs
時間枠:Up to approximately week 115
|
Part A and B |
Up to approximately week 115
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinical dosimetry based on tissue radiation absorbed dose calculated from positron emission tomography (PET) image acquisition data
時間枠:On days 1, 5 and 8
|
After injection of 37 megabecquerel (MBq) of 89Zr-DFO-REGN5054, a series of whole-body positron emission tomography (PET) images will be obtained over a period of up to 8 days and corrected for attenuation by low-dose computed tomography (CT) scans using PET/CT. The radiation effective dose per organ/tissue will be calculated for each organ using Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA/EXM). The unit of effective dose per organ/tissue will be millisievert per Minimum Base Quantity (MBq) for each participant's organ/tissue. The final values for each organ will be averaged across participants for each mass dose |
On days 1, 5 and 8
|
|
Clinical dosimetry based on tissue radiation effective dose calculated from PET image acquisition data
時間枠:On days 1, 5 and 8
|
After injection of 37 MBq of 89Zr-DFO-REGN5054, a series of whole-body PET images will be obtained over a period of up to 8 days and corrected for attenuation by low-dose CT scans using PET/CT. The radiation effective dose for the whole body will be calculated using OLINDA/EXM software. The unit of effective dose will be millisievert per MBq for the whole body for each participant. The final values will be averaged across participants for each mass dose. |
On days 1, 5 and 8
|
|
Concentration of 89Zr-DFO-REGN5054 in serum
時間枠:On days 1, 5 and 8
|
Part A |
On days 1, 5 and 8
|
|
Serum imaging agent activity concentration of area under the curve (AUC0-7)
時間枠:Up to day 8
|
Part A |
Up to day 8
|
|
89Zr-DFO-REGN5054 uptake across cluster of differentiation 8 (CD8)-expressing normal tissues and tumors
時間枠:At the time of imaging, up to day 8
|
Part A and Part B |
At the time of imaging, up to day 8
|
|
Blood pool uptake of 89Zr-DFO-REGN5054 with subsequent calculation of standardized uptake value (SUV) tumor-to-blood ratios
時間枠:At the time of imaging, up to day 8
|
Part A and Part B |
At the time of imaging, up to day 8
|
|
Association of 89Zr˗DFO˗REGN5054 autoradiographic signal intensity distribution with CD8 expression in tumor tissues
時間枠:At Baseline
|
Part A and Part B |
At Baseline
|
|
Association of 89Zr-DFO-REGN5054 uptake with CD8 expression in tumor tissues
時間枠:At Baseline
|
Part B |
At Baseline
|
|
Association of tumor-to-blood ratio of 89Zr-DFO-REGN5054 with CD8 expression in tumor tissues
時間枠:At Baseline
|
Part B |
At Baseline
|
協力者と研究者
捜査官
- スタディディレクター:Clinical Trials Management、Regeneron Pharmaceuticals
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- R5054-ONC-1843
- 2019-001604-38 (EudraCT番号)
- 2019 (米国 NIH グラント/契約)
- 2024-515351-37-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD 共有時間枠
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共有アクセス基準
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。